Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Aug 9;6(11):e1356148.
doi: 10.1080/2162402X.2017.1356148. eCollection 2017.

The prognostic role of tumor infiltrating T-lymphocytes in squamous cell carcinoma of the head and neck: A systematic review and meta-analysis

Emma J de Ruiter  1 , Marc L Ooft  1 , Lot A Devriese  2 , Stefan M Willems  1
Affiliations
Review

The prognostic role of tumor infiltrating T-lymphocytes in squamous cell carcinoma of the head and neck: A systematic review and meta-analysis

Emma J de Ruiter et al. Oncoimmunology. .

Abstract

Background - The presence of tumor-infiltrating lymphocytes (TILs) in the tumor microenvironment is associated with an improved prognosis and a better response to therapy in different types of cancer. In this systematic review and meta-analysis, we investigated the prognostic value of T cells in head and neck squamous cell carcinoma (HNSCC). Methods - In a systematic review, Pubmed and Embase were searched for publications that investigated the prognostic value of T cells in HNSCC. A meta-analysis was performed including all studies assessing the association between CD3+, CD4+, CD8+, and FoxP3+ TILs and overall survival (OS), disease-free survival (DFS), or locoregional control (LRC). Results - A pooled analysis indicated a favorable, prognostic role for CD3+ TILs (HR 0.64 (95%CI 0.47-0.85) for OS, HR 0.63 (95%CI 0.49-0.82) for DFS) and CD8+ TILs (HR 0.67 (95%CI 0.58-0.79) for OS, HR 0.50 (95%CI 0.37-0.68) for DFS, and HR 0.82 (95%CI 0.70-0.96) for LRC) in the clinical outcome of HNSCC. FoxP3+ TILs were also associated with better OS (HR 0.80 (95%CI 0.70-0.92)). Conclusion - This systematic review and meta-analysis confirmed the favorable, prognostic role of CD3+ and CD8+ T cell infiltration in HNSCC patients and found an association between FoxP3+ TILs and improved overall survival. Future studies using homogeneous patient cohorts with regard to tumor subsite, stage and treatment are necessary to provide more insight in the predictive value of TILs in HNSCC.

Keywords: T cells; head and neck squamous cell carcinoma (HNSCC); prognostic biomarkers; systematic review; tumor infiltrating lymphocytes (TILs).

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Selection process. Of the 122 articles that remained after the initial title/abstract screening, 28 remained for inclusion.
Figure 2.
Figure 2.
Forest plots of prognostic value of CD3+ TILs on overall survival, disease-free survival and locoregional control in HPV-negative patients (A) and HPV-positive patients (B). No data were available for disease-free survival in HPV-positive patients.
Figure 3.
Figure 3.
Forest plots of prognostic value of CD4+ TILs on overall survival, disease-free survival and locoregional control in HPV-negative patients (A) and HPV-positive patients (B). No data were available for disease-free survival in HPV-positive patients.
Figure 4.
Figure 4.
Forest plots of prognostic value of CD8+ TILs on overall survival, disease-free survival and locoregional control in HPV-negative patients (A) and HPV-positive patients (B).
Figure 5.
Figure 5.
Forest plots of prognostic value of FoxP3+ TILs on overall survival, disease-free survival and locoregional control in HPV-negative patients (A) and HPV-positive patients (B).
See this image and copyright information in PMC

References

    1. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet. 2008;371(9625):1695-709. doi:10.1016/S0140-6736(08)60728-X. PMID:18486742 - DOI - PMC - PubMed
    1. Murdoch D. Standard, and novel cytotoxic and molecular-targeted, therapies for HNSCC: An evidence-based review. Curr Opin Oncol. 2007;19(3):216-21. doi:10.1097/01.cco.0000264952.98166.99. PMID:17414639 - DOI - PubMed
    1. Hadrup S, Donia M, Thor Straten P. Effector CD4 and CD8 T cells and their role in the tumor microenvironment. Cancer Microenviron. 2013;6(2):123-33. doi:10.1007/s12307-012-0127-6. PMID:23242673 - DOI - PMC - PubMed
    1. Curry JM, Sprandio J, Cognetti D, Luginbuhl A, Bar-ad V, Pribitkin E, Tuluc M. Tumor microenvironment in head and neck squamous cell carcinoma. Semin Oncol. 2014;41(2):217-34. doi:10.1053/j.seminoncol.2014.03.003. PMID:24787294 - DOI - PubMed
    1. Bauml J, Seiwert TY, Pfister DG, Worden F, Liu SV, Gilbert J, Saba NF, Weiss J, Wirth L, Sukari A, et al.. Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: Results from a single-arm, phase II study. J Clin Oncol. 2017;35(14):1542-9. doi:10.1200/JCO.2016.70.1524. PMID:28328302 - DOI - PMC - PubMed

Publication types

LinkOut - more resources